Table 3.
Meta-analysis results for B cell NHL subtypes
| Comparison of summary ORs‡ |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Q test† |
Summary OR | DLBCL |
Follicular lymphoma |
|||||||
| Biomarker | Outcome | No. | I2* (95% CI) | Statistic | P | OR (95% CI) | ROR (95% CI) | P | ROR (95% CI) | P |
| IL-6 | CLL/SLL/PLL | 4 | 0 (0 to 0) | 0.19 | .996 | 0.98 (0.92 to 1.06) | 1.15 (0.99 to 1.34) | .074 | 0.97 (0.87 to 1.09) | .652 |
| DLBCL | 6 | 0 (0 to 74) | 4.80 | .570 | 1.13 (0.99 to 1.30) | 1.00 (reference) | 0.85 (0.72 to 1.00) | .044 | ||
| Follicular lymphoma | 5 | 9 (0 to 81) | 4.41 | .492 | 0.96 (0.88 to 1.05) | – | 1.00 (reference) | |||
| IL-10 | CLL/SLL/PLL | 4 | 78 (41 to 92) | 13.76 | .008 | 1.09 (0.88 to 1.34) | 1.04 (0.83 to 1.29) | .747 | 1.01 (0.81 to 1.26) | .955 |
| DLBCL | 5 | 45 (0 to 80) | 7.28 | .201 | 1.13 (1.06 to 1.21) | 1.00 (reference) | 0.97 (0.87 to 1.07) | .485 | ||
| Follicular lymphoma | 5 | 66 (13 to 87) | 11.93 | .036 | 1.09 (1.02 to 1.18) | – | 1.00 (reference) | |||
| TNF-α | CLL/SLL/PLL | 4 | 0 (0 to 66) | 1.34 | .854 | 1.15 (1.04 to 1.27) | 0.91 (0.73 to 1.14) | .410 | 1.21 (0.89 to 1.65) | .214 |
| DLBCL | 5 | 62 (0 to 86) | 10.41 | .064 | 1.04 (0.85 to 1.28) | 1.00 (reference) | 1.34 (0.94 to 1.90) | .107 | ||
| Follicular lymphoma | 5 | 66 (12 to 87) | 11.82 | .037 | 1.39 (1.04 to 1.86) | – | 1.00 (reference) | |||
| CXCL13 | CLL/SLL/PLL | 4 | 77 (36 to 91) | 12.81 | .012 | 1.43 (0.97 to 2.11) | 1.18 (0.65 to 2.12) | .584 | 1.20 (0.61 to 2.37) | .604 |
| DLBCL | 4 | 85 (61 to 94) | 19.43 | .001 | 1.69 (1.08 to 2.62) | 1.00 (reference) | 1.02 (0.50 to 2.08) | .964 | ||
| Follicular lymphoma | 3 | 86 (60 to 95) | 14.38 | .002 | 1.71 (0.98 to 3.00) | – | 1.00 (reference) | |||
| sCD23 | CLL/SLL/PLL | 2 | 99 (97 to 99) | 69.59 | .000 | 2.62 (0.74 to 9.19) | 0.48 (0.14 to 1.69) | .253 | 0.75 (0.21 to 2.71) | .664 |
| DLBCL | 3 | 49 (0 to 85) | 3.90 | .272 | 1.25 (1.11 to 1.41) | 1.00 (reference) | 1.57 (1.19 to 2.08) | .001 | ||
| Follicular lymphoma | 1 | —§ | 0.00 | 1.000 | 1.97 (1.53 to 2.53) | – | 1.00 (reference) | |||
| sCD27 | CLL/SLL/PLL | 3 | 95 (89 to 98) | 39.81 | <.001 | 2.03 (0.73 to 5.64) | 1.06 (0.29 to 3.83) | .927 | 1.08 (0.22 to 5.16) | .927 |
| DLBCL | 4 | 89 (74 to 95) | 26.90 | <.001 | 2.15 (0.99 to 4.67) | 1.00 (reference) | 1.01 (0.25 to 4.18) | .985 | ||
| Follicular lymphoma | 2 | 94 (81 to 98) | 16.56 | <.001 | 2.18 (0.67 to 7.16) | – | 1.00 (reference) | |||
| sCD30 | CLL/SLL/PLL | 4 | 76 (35 to 91) | 12.70 | .013 | 1.23 (1.05 to 1.44) | 1.38 (0.84 to 2.26) | .205 | 1.89 (1.07 to 3.35) | .028 |
| DLBCL | 5 | 88 (74 to 94) | 32.94 | <.001 | 1.69 (1.06 to 2.71) | 1.00 (reference) | 1.37 (0.67 to 2.82) | .387 | ||
| Follicular lymphoma | 3 | 87 (64 to 96) | 15.66 | .001 | 2.33 (1.35 to 4.01) | – | 1.00 (reference) | |||
Higgins' I2 statistic measuring the proportion of the observed variance between studies relative to the total variance of a set of studies. CI = confidence interval; CLL/SLL/PLL = chronic lymphocytic leukemia/small lymphocytic lymphoma/prolymphocytic leukemia; DLBCL = diffuse large B-cell lymphoma.
Q test assessing the degree to which study effect sizes are concordant.
ORs and P values for comparisons of estimates between outcomes for each biomarker. Each ROR compares the odds ratio for the column biomarker to that of the row biomarker as reference, for example for IL-6 ORDLBCL/ORCLL/SLL/PLL=1.15, with corresponding Wald-type confidence interval computed using the square root of the sum of the OR variances.
Em dash “—” denotes statistics that were not calculated because of inadequate sample size. En dash “–” indicates omitted results comparing DLBCL to Follicular lymphoma which are exact inverses of results comparing Follicular lymphoma to DLBCL in the subsequent colum.